A venture capital firm based in the USA with a presence in China, has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. The firm seeks to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies globally, with a focus on those in USA, Europe, and China.
The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.
The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based VC With China Presence Actively Seeks Life Science Investment Opportunities, Most Interested in Medical Device Companies
13 JanSubscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 
Leave a Reply